Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: Linking cardiometabolic and neuropsychiatric diseases
Stanislav Yanev, Institute of Neurobiology, Department of Drug Toxicology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria
Luigi Aloe, Marco Fiore, Institute of Cellular Biology and Neurobiology, National Research Council, I-00168 Rome, Italy
George N Chaldakov, Laboratory of Cell Biology, Department of Anatomy and Histology, Medical University, BG-9002 Varna, Bulgaria
Author contributions: All the authors contributed to this paper equally.
Correspondence to: George N Chaldakov, MD, PhD, Laboratory of Cell Biology, Department of Anatomy and Histology, Medical University, 55 Marin Drinov Street, BG-9002 Varna, Bulgaria. chaldakov@yahoo.com
Telephone: +359-52-754394 Fax: +359-52-650019
Received: July 30, 2013
Revised: September 20, 2013
Accepted: October 16, 2013
Published online: December 9, 2013
Revised: September 20, 2013
Accepted: October 16, 2013
Published online: December 9, 2013
Core Tip
Core tip: Previously we reviewed an enlarged list of metabotrophins including the adipose-produced nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), leptin and adiponectin as relevant to cardiometabolic, neurological and psychiatric diseases (Riv Psichiatr 2009; 44: 79-87). Now we update the growing body of evidence that NGF-BDNF/TrkA, B dysfunction may synergistically leads to both cardiometabolic and neuropsychiatric diseases. This may help to construct a conceptually novel therapeutic approach for future studies in the field of translational pharmacology of NGF and BDNF.